In recent years, PCa fusion genes (specifically TMPRSS2-ERG fusion) have been identified as oncogenic drivers with the potential for patient stratification and as targets for effective prevention/intervention strategies in drug efficacy trials. Here, ERG is linked to posterior cortical atrophy.